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Posterolateral lumbar arthrodesis is used to treat many 
spinal conditions, such as scoliosis, stenosis, spondylolis-
thesis and degenerative disc disease. Its two primary short-
comings are the morbidity associated with the harvesting 
of an autogenous iliac bone graft  ,
1-4) and the risk of pseud-
arthrosis.
4) Calcium phosphate ceramics, such as hydroxy-
apatite (HA) and β-tricalcium phosphate (β-TCP), are well 
Background: Porous β-calcium pyrophosphate (β-CPP) was developed to improve the fusion success of posterolateral lumbar fu-
sion (PLF). The possibility of accomplishing PLF using a mixture of porous β-CPP and iliac bone was studied. This paper reports the 
radiologic results of PLF using the β-CPP plus autograft for lumbar degenerative disease as a bone graft extender.
Methods: A prospective, case-matched, radiographic study evaluating the results of short segment lumbar fusion using a β-CPP 
plus autograft was performed to compare the efﬁ  cacy of β-CPP plus autograft with that of an autograft alone for short segment 
lumbar fusion. Thirty one consecutive patients (46 levels) underwent posterolateral fusion with pedicle screw ﬁ  xation and addi-
tional posterior lumbar interbody fusion. In all patients, 3 mL of β-CPP plus 3 mL of autogenous bone graft was placed randomly in 
one side of a posterolateral gutter, and 6 mL of autogenous iliac bone graft was placed on the other. The fusion rates, volumes of 
fusion masses, and bone absorption percentage were evaluated postoperatively using simple radiographs and 3 dimensional com-
puted tomography (3D-CT) scans. 
Results: The control sides treated with an autograft showed signiﬁ  cantly better Lenke scores than the study sides treated with 
β-CPP at 3 and 6 months postoperatively, but there was no difference between the two sides at 12 months. The fusion rates (con-
ﬁ  rmed by 3D-CT) were 87.0% in the β-CPP group and 89.1% in the autograft group, which were not signiﬁ  cantly different. The 
fusion mass volumes and bone absorption percentage at 12 months postoperatively were 2.49 mL (58.4%) and 1.89 mL (69.5%) for 
the β-CPP and autograft groups, respectively, and mean fusion mass volume was signiﬁ  cantly higher in the β-CPP group.
Conclusions: β-CPP combined with an autograft is as effective as autologous bone for grafting during instrumented posterolat-
eral spinal fusion. These ﬁ  ndings suggest that β-CPP bone chips can be used as a novel bone graft extender for short-segment 
posterolateral spinal fusion.
Keywords: Beta-calcium pyrophosphate, Bone graft extender, Fusion rate, Lumbar posterolateral fusion, Prospective consecutive 
study239
Lee et al. Beta-Calcium Pyrophosphate as a Bone Graft   Extender in Instrumented PLF
Clinics in Orthopedic Surgery • Vol. 3, No. 3, 2011 • www.ecios.org
known bone graft extenders that exhibit bioactivity, and 
form chemical bonds directly with natural bone. On the 
other hand, these two types of calcium phosphate ceramics 
have drawbacks. HA has excellent osteoconductivity and 
biocompatibility but the resorption rate is so low that it 
remains in the living body for a long time. β-TCP is biode-
gradable and might not provide the temporary persistence 
required as a scaff  old for the formation of bone.
5) A low fu-
sion rate of β-TCP compared to that of HA was observed 
in the rabbit posterolateral fusion model.
6) Accordingly, if 
ceramics with the same degree of osteoconductivity as HA, 
and lower biodegradability than β-TCP but better than 
that of HA can be developed, they might be a more ideal 
bone graft   extender. 
Studies have shown that β-calcium pyrophosphate 
(β-CPP) provides an alternative graft   material that is bio-
active, non-toxic
7) and is incorporated more completely 
and resorbed more rapidly than porous HA in a canine 
model.
5) Moreover, β-CPP has an excellent fusion rate 
compared to several other porous calcium phosphate ce-
ramics in a rabbit intertransverse process fusion model,
6) 
and that it also has a positive eff  ect as a coating material 
during the initial stages aft  er titanium screw fi  xation in a 
canine model.
8) On the other hand, few reports are avail-
able on the merits of β-CPP used as a bone graft   extender. 
Th  is  prospective  in vivo study compared the use of a po-
rous synthetic β-CPP (Bongros
®-CP) as a novel bone graft   
extender in a posterolateral spine fusion model with a 
100% autograft  . 
METHODS
A previous report on the use of HA described the meth-
ods used in this study in detail.
9) Between May 2004 and 
May 2005, 33 consecutive patients (48 levels) with spinal 
stenosis, or grade I or grade II spondylolisthesis, who 
underwent decompression and one- or two-level pedicle 
screw instrumented spinal fusion, were recruited pro-
spectively after obtaining approval from the institutional 
review board and the Korean Food and Dug Administra-
tion. Informed consent was obtained from all participants. 
All patients were treated by the same operation team and 
underwent combined interbody fusion with the placement 
of 2 titanium alloy cages using local morselized bone for 
one level and additional posterolateral fusion using β-CPP 
with an iliac bone graft   on one side and iliac bone graft   on 
the other side. Th   e inclusion criteria were lumbar posteri-
or interbody fusion and posterolateral fusion with pedicle 
screw fixation. The exclusion criteria were an infection, 
malignancy, pregnancy, abnormal laboratory findings or 
metabolic bone disease, a liver function abnormality, or 
aged over 75 or under 18.
9) The mean age of the patients 
was 63.3 (range, 46 to 73 years), and there were 25 women 
and 8 men. All patients were followed up for at least 12 
months. 
Bone Graft   Substitute
Bongros
®-CP (Bioalpha, Seongnam, Korea) is composed 
of highly pure, synthetic calcium pyrophosphate (Ca2P2O7), 
and has a trabecular structure that resembles the 3-dimen-
sional interconnected pore structure of human cancellous 
bone (pore size, 300 μm; porosity, 80%; particle size, 3.0 to 
6.0 mm) (Fig. 1).
Surgical Techniques
A standard posterior lumbar interbody fusion technique 
Fig. 1. Bongros-CP. (A) Macroscopic appearance of Bongros-CP. (B) Scanning electron microscopy image of Bongros-CP.240
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with laminectomies, medial facetectomies, discectomies, 
and transpedicular screw/rod instrumentation was per-
formed on all patients. Autograft  s, which were harvested 
locally during decompression, were morselized and packed 
into the disc spaces with titanium alloy cages. Autogenous 
iliac crest bone was also harvested and morselized. De-
cortication of the transverse processes and lateral facet 
surfaces were performed before β-CPP with an autograft   
mixture or autograft   bone implantations.
10-12)
Th   e test material (3 mL of β-CPP and 3 mL of au-
togenous iliac bone) was inserted in one side and the con-
trol material (6 mL of autogenous iliac bone) was inserted 
into the other side in each patient in a random manner. 
Th   erefore, the patients served as their own controls.
13) Th  e 
postoperative management protocols were the same for all 
patients including perioperatice pain control.
9)   
Clinical and Radiological Assessments
Radiographic evaluation of fusion using plane radiographs 
with standing lumbosacral anteroposterior, standing lat-
eral, standing lateral fl  exion, and standing lateral extension 
images were made 3, 6, and 12 months postoperatively. 
Th   ree dimensional thin cut (1 mm) CT images were ob-
tained at 12 months postoperatively and reconstructed 
axially, sagittally and coronally. All imaging studies were 
evaluated for evidence of fusion by three independent or-
thopedic surgeons in a blind manner. Th   e CT assessments 
of fusion were described in our previous report
9) including 
continuous trabecular bone between transverse processes, 
cortication at the peripheral edges of fusion masses, and 
of the absence of identifi  able radiographic cleft  s (Fig. 2).
14) 
Th   e instrumented spinal level were considered when three 
observers found no radiographic evidence of nonunion. 
Fusion of the sides was defi  ned as bridging at all levels. Fu-
sions were classifi  ed using Lenke’s classifi  cation
15) at 3, 6, 
and 12 months postoperatively. At 12 months, the volume 
of the fusion masses on either side of the vertebrae were 
assessed by 3 dimensional computed tomography (3D-CT) 
scans and compared using Rapidia (version 2.8, Infinitt, 
Seoul, Korea). To measure the volume of the fusion mass, 
sequential CT scans with a 1 mm collimation and 1 mm 
scan spacing were obtained 12 months aft  er surgery.
9) To 
Fig. 2. Three dimensional computed 
tomography (3D-CT) scan 12 months after 
an L4-L5 instrumented lumbar fusion 
utilizing a β-tricalcium phosphate (β-TCP) 
+ autograft (calcium pyrophosphate, CPP) 
and autograft (Auto). Note the continuity 
of the β-CPP and bone fragments over 
the transverse processes. (A) Coronal 
reconstruction of β-CPP. (B) Coronal 
reconstruction of autograft. (A) and (B), 
coronal reconstruction of a CT scan 
demonstrates the incorporation of 
β-CPP through the matrix. (C) Sagittal 
reconstruction of β-CPP. (D) Sagittal 
reconstruction of the autograft. (C) and 
(D), Sagittal reconstruction of a CT scan 
demonstrates that the continuous bony 
mass is present bilaterally with no 
evidence of lucent lines.   241
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measure the volume of the fusion mass, two independent 
spine surgeons measured the area of the fusion mass using 
the manual cursor technique and the volume of the fusion 
mass was summated at each cross-sectional volume which 
was estimated using the cross-sectional area multiplied by 
the slice thickness (1 mm).
9,11) Th   e absorption percentage 
of the autograft β-CPP were also calculated by the same 
method of previous report.
9)
The vital signs, subjective symptoms and labora-
tory results were evaluated preoperatively and 3, 6, and 12 
months aft  er surgery. A paired-sample t-test was used to 
identify significant radiological differences between the 
two treatments. Statistical signifi  cance was accepted at the 
p < 0.05 level, and the analysis was performed throughout 
using SPSS ver. 11.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Overall, out of 33 patients (48 segments), a total of 31 (46 
segments) were available for a 3D-CT evaluation at the 
12 month follow-up. Table 1 lists the fi  nal patient demo-
graphics. Th   e mean Lenke score on the 3-month follow-up 
radiograph in the autograft   group (1.35) was signifi  cantly 
lower than that of the β-CPP + autograft mixture group 
(2.15; p < 0.01), as were Lenke scores at the 6-month fol-
low-up (1.13 vs. 1.47, respectively; p < 0.01), but not at 12 
months (1.13 vs. 1.22, respectively; p > 0.05) (Table 2). On 
the other hand, the Lenke scores, which were confirmed 
by the 3D-CT scans at 12 months, were 1.2 and 1.22 for 
autograft   and β-CPP + autograft   group, respectively, which 
was not signifi  cantly diff  erent (p > 0.05).
The number of levels showing complete fusion in 
the autograft   and β-CPP + autograft   group at 12 months 
was 41 (89.1%) and 40 (87.0%), respectively, which was 
not signifi  cantly diff  erent. Th   e mean fusion mass volumes 
and mean fusion mass absorption percentage were signifi  -
cantly diff  erent in the two groups at 12 months postopera-
tively according to 3D-CT. In particular, the mean volume 
in the autograft group (1.89 mL) was significantly lower 
(p < 0.01) than that in the β-CPP + autograft   group (2.49 
mL), and the mean absorption percentage in the autograft   
group (69.5%) was also signifi  cantly higher (p < 0.01) than 
that in the β-CPP + autograft   group (58.4%) (Table 3). Th  e 
mean absorption percentage of β-CPP was 48.5% and its 
mean relative absorption percentage versus the autograft   
was 69.8%. 
No definite postoperative complications, e.g., in-
fection, abnormal vital signs or abnormal lab findings 
(including calcium and phosphorous levels), were encoun-
Table 1. Patient Characteristics and Fusion Levels  
Variables No. of cases 
(levels)
% of cases
(levels)
Sex Male 7 (8) 22.6 (17.4)
Female 24 (38) 77.4 (82.6)
Total 31 (46) 100.0 (100.0)
Age 40-49 2 (2) 6.4 (4.3)
50-59   8 (11) 25.8 (23.9)
60-69 15 (21) 48.4 (45.7)
70+   6 (12) 19.4 (26.1)
Total 31 (46) 100.0
Level L1-2 (1)     2.1
L2-3 (4)     8.7
L3-4 (9)   19.6
L4-5 (24)   52.2
L5-S1 (8)   17.4
Total (46) 100.0
β-CPP
 insertion site Right 24   52.2
Left 22   47.8
Total 46 100.0
β-CPP: β-calcium pyrophosphate.
Table 2. Paired Samples Statistics for the Lenke Score Results from 
the Radiographs 
Variables Mean ± SD No. p-value
3 mo < 0.01
Auto 1.35 ± 0.52 48
β-CPP 2.15 ± 0.41 48
6 mo < 0.01
Auto 1.13 ± 0.33 47
β-CPP 1.47 ± 0.50  47
12 mo  > 0.05
Auto 1.13 ± 0.33 46
β-CPP 1.22 ± 0.36 46
Overall 33 patients (48 segments), 32 patients (47 segments) were followed-
up at 6 mo after surgery and a total of 31 patients (46 segments) were 
followed-up at 12 mo after surgery.
SD: standard deviation, β-CPP: β-calcium pyrophosphate.242
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tered in either group.
DISCUSSION
Calcium phosphate ceramics, such as Ca10(PO4)6(OH)2(HA), 
β-Ca3(PO4)2(β-TCP), and β-Ca2P2O7, are bioactive, or 
more specifi  cally have the ability to form chemical bonds 
directly with natural bone.
16-19) Transmission electron mi-
croscopy of the interfaces of bone and Ca2P2O7 ceramics 
has shown that β-CPP is biocompatible, like β-TCP and 
HA.
15) HA and other complex calcium phosphate salts are 
the end products of the biological mineralization process, 
and β-CPP is formed during this process,
20) and has a bio-
logical response in terms of new bone development, which 
is similar to that of HA.
17) Some researchers view β-CPP 
as a new biodegradable ceramic material
21-23) because it 
is more biocompatible than hydroxyapatite.
22) The Ca/P 
ratio of β-CPP is 1, which is far lower than that of β-TCP, 
and is potentially more biodegradable than β-TCP. On the 
other hand, β-TCP is more biodegradable than β-CPP and 
β-CPP is more biodegradable than HA. Th  erefore,  β-CPP 
was selected as a new bone graft   extender. 
In the present study, clinical assessments (e.g., Visual 
Analogue Scale pain score, Short Form-36, and Oswestry 
Disability Index) were not included because the test mate-
rial and control material was inserted on opposite sides in 
the same patients. 
Th   e most important parameter in terms of an evalu-
ation of the effectiveness of newly manufactured bone 
graft extenders is the fusion rate. Therefore, precise as-
sessments of the fusion rates are critical, and the use of 
fine-cut CT scans with sagittal and coronal reconstruc-
tions might increase the accuracy of fusion assessments.
24) 
Th   erefore, the use of 3D-CT to evaluate the presence of a 
successful arthrodesis is a major strength of the present 
study because thin-section CT scans allow bony disconti-
nuities to be discerned more easily.
14) 
One problem that should be considered is whether 
the posterolateral fusion rates were increased slightly by 
the additional posterior lumbar interbody fusion with cage 
insertion. The use of supplementary instrumentation is 
controversial, as the fusion rates may be improved.
25-28) In 
the present study, any additional stability would have af-
fected the fusion rates on both sides equally. Hence, cage 
insertion would not be expected to alter the relative fusion 
rates of the two groups. Th   e other problem is whether ad-
ditional posterior lumbar interbody fusion was needed in 
this study. Because β-CPP has not been used previously 
in humans, the posterolateral spinal fusion rates could 
not be estimated. Consequently, this study was designed 
intentionally to minimize the risk of nonunion by intro-
ducing additional posterior lumbar interbody fusion and 
to evaluate the eff  ectiveness of β-CPP by adding a minimal 
amount of autograft. Indeed, the fusion rates in the in-
tertransverse process area in another study varied widely 
from 60% to 98%.
29) On the other hand, the fusion rate of 
the autograft   in the present study was only 89.1% despite 
the additional cage insertion, which is probably due to the 
insertion of a relatively small amount (6 mL) of autograft  . 
Moreover, the additional interbody fusion by the cages im-
parted strong stability to both posterolateral fusion masses 
to the same degree. Although this instrumentation cannot 
eliminate the fl  aws in this study design, pedicle screw and 
rod fixation with additional interbody fusion with cages 
might minimize the eff  ects of fusion on one side on fusion 
on the other side.
9)
Th   e most important result of the present study was 
that the fusion rates, as confirmed by the 3D-CT scans, 
were similar in the two groups, which indicates that 
β-CPP provides adequate fusion. This signifies the pos-
sibility of a mixture of β-CPP and autograft   being used as 
bone graft   extender. Th   e absorption percentage of β-CPP 
(48.5%) was signifi  cantly lower than that of the autograft   
(69.5%) but higher than that of HA (43.5%) based on our 
institute’s data.
9) Moreover, the relative absorption percent-
age of β-CPP versus the autograft   (69.8%) was also higher 
than that of HA versus autograft (55.6%).
7) This may be 
the advantage of β-CPP over relatively slowly absorbed 
bone graft extenders, such as HA or apatite-wollastonite 
glass-ceramics. The advantages of biodegradable materi-
Table 3. Paired Sample Statistics for the CT Lenke Scores, CT Graft 
Volumes, and CT Resorption Rates at 12 Months  
Variables Mean ± SD No. p-value
CT Lenke scores 0.840
  Auto 1.2 ± 0.66 46
  β-CPP 1.22 ± 0.67 46
CT graft volumes (mm
3) < 0.01
  Auto 1,890.9 ± 898.6 46
  β-CPP    2,492.5 ± 1,140.5 46
Resorption rates of fusion mass (%)
  Auto 69.5 ± 15.0 46
  β-CPP 58.4 ± 19.0 46 < 0.01
CT: computed tomography, SD: standard deviation, β-CPP: β-calcium 
pyrophosphate.243
Lee et al. Beta-Calcium Pyrophosphate as a Bone Graft   Extender in Instrumented PLF
Clinics in Orthopedic Surgery • Vol. 3, No. 3, 2011 • www.ecios.org
als are evident in that no foreign body remains in the long 
term. Moreover, after the porous ceramic material has 
degraded, the remodeled bone is stronger than a ceramic/
newly formed bone combination.
30) Complete biological 
and physiologic bone healing can be achieved by implant-
ing biodegradable bioceramics. Although β-TCP, calcium 
carbonate (CaCO3), and calcium sulfate (CaSO4) are bio-
degradable, none of these are eff  ective bone graft   extend-
ers for spinal intertransverse process fusion.   
In view of the above, rapid absorption must be 
matched by excellent osseointegration, even in difficult 
fusion beds, such as those that have been infected or ra-
diated, and be located near scar tissue, or extraosseous 
fusion beds, such as the intertransverse process area. To 
achieve successful fusion in such difficult environments, 
the osteoconductivity of the implanted material and the 
maintenance of porous structures until bone ingrowth has 
occurred from the fusion bed into the graft   pores are criti-
cal. Moreover, β-CPP has excellent osteoconductivity and 
the property of maintaining a porous structure, which are 
the reasons why β-CPP can be used during posterolateral 
fusion of the spine. 
In conclusion, the described β-CPP/autograft mix 
achieved successful posterolateral spinal fusion in the pres-
ence of instrumentation, and it has absorption properties. 
There were no signs of toxicity or abnormal laboratory 
fi  ndings in any patient in this study. Th   erefore, β-CPP can 
be used as a novel bone graft   extender for intertransverse 
process fusion with short-segment instrumentation.
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